ZAI LAB (09688.HK) shares surged 5.15% in Friday's pre-market trading session following the company's announcement that it complies with the Holding Foreign Companies Accountable Act (HFCAA) and is not subject to delisting. This development has significantly boosted investor confidence in the Chinese biopharmaceutical company.

The HFCAA, enacted in 2020, requires foreign companies listed on U.S. stock exchanges to comply with American auditing standards. Companies that fail to meet these requirements risk being delisted from U.S. exchanges. ZAI LAB's compliance with the HFCAA ensures its continued listing on major exchanges, providing stability and accessibility for international investors.

This positive news is likely to have a lasting impact on ZAI LAB's stock performance and investor sentiment. By avoiding the risk of delisting, the company has removed a significant uncertainty that has been weighing on many Chinese stocks listed in the United States. As a result, investors may view ZAI LAB as a more stable and attractive investment opportunity in the competitive biopharmaceutical sector.